BioMarin Pharmaceutical Inc. announced on Friday that it will acquire Amicus Therapeutics in a deal valued at approximately $4.8 billion, marking a significant expansion of its rare disease business and product lineup.
Under the agreement, BioMarin — a California-based biotechnology company — will pay $14.50 per share in cash, representing a 33.1 % premium over Amicus’ most recent closing stock price.
Strategic Rationale & Product Line Expansion
The acquisition gives BioMarin access to two approved therapies developed by Amicus that target rare genetic disorders:
- Galafold (migalastat) — an oral treatment for Fabry disease;
- Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) — a combination therapy for Pompe disease.
These therapies generated approximately $599 million in combined revenue over the past year, strengthening BioMarin’s position in rare metabolic disease treatment.
BioMarin will also gain the U.S. rights to DMX-200, an investigational treatment for focal segmental glomerulosclerosis (FSGS) — a rare and severe kidney disease currently in late-stage development.
Financing and Expected Impact
The acquisition will be financed through cash on hand and roughly $3.7 billion in non-convertible debt. BioMarin expects the deal to add revenue immediately upon closing and become materially accretive to adjusted earnings within the first year after completion.
The transaction is anticipated to close in the second quarter of 2026, subject to customary regulatory approvals and shareholder consents.
Market Reaction & Outlook
Following the announcement, Amicus shares surged sharply, reflecting investor confidence in the takeover premium and BioMarin’s strategy. BioMarin’s own stock also moved higher in early trading.
Industry analysts see the deal as a key step in positioning BioMarin as a leader in rare disease therapeutics, diversifying its portfolio and potentially accelerating long-term growth amid heightened M&A activity in biotech.
